BIT 3.45% 2.8¢ biotron limited

E Protien of Corona Virus, page-30

  1. 2,879 Posts.
    lightbulb Created with Sketch. 303
    I think BMD. Posted this from the Saudi Paper. Gee How much more PROOF do we need for Biotron to say BIT225 is effective against COVID19.
    Abstract
    The spread of the novel coronavirus (SARS-CoV-2) has triggered a global emergency, that demands urgent solutions for detection and therapy to prevent escalating health, social and economic impacts. The spike protein (S) of this virus enables binding to the human receptor
    1 ACE2, and hence presents a prime target for vaccines preventing viral entry into host cells .
    2
    The S proteins from SARS-CoV-1 and SARS-CoV-2 are similar , but structural differences in
    the receptor binding domain (RBD) preclude the use of SARS-CoV-1–specific neutralizing
    3
    antibodies to inhibit SARS-CoV-2 . Here we used comparative pangenomic analysis of all
    sequenced Betacoronaviruses to reveal that, among all core gene clusters present in these viruses, the envelope protein E shows a variant shared by SARS and SARS-Cov2 with two completely-conserved key functional features, an ion-channel and a PDZ-binding Motif (PBM). These features trigger a cytokine storm that activates the inflammasome, leading to
    4-6 increased edema in lungs causing the acute respiratory distress syndrome (ARDS) , the
    7,8
    leading cause of death in SARS-CoV-1 and SARS-CoV-2 infection
    approved for human use may inhibit SARS-CoV-1 and SARS-CoV-2 Protein E, either acting upon the ion channel (Amantadine and Hexamethylene amiloride9,10) or the PBM (SB2035805), thereby potentially increasing the survival of the host, as already demonstrated for SARS-CoV-1in animal models. Hence, blocking the SARS protein E inhibits development of ARDS in vivo. Given that our results demonstrate that the protein E subcluster for the SARS clade is quasi-identical for the key functional regions of SARS-CoV-1 and SARS-CoV-2, we conclude that use of approved drugs shown to act as SARS E protein inhibitors can help prevent further casualties from COVID-2019 while vaccines and other preventive measures are being developed
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
(20min delay)
Last
2.8¢
Change
-0.001(3.45%)
Mkt cap ! $25.26M
Open High Low Value Volume
2.8¢ 2.9¢ 2.8¢ $2.114K 75.44K

Buyers (Bids)

No. Vol. Price($)
1 87026 2.8¢
 

Sellers (Offers)

Price($) Vol. No.
2.9¢ 45600 1
View Market Depth
Last trade - 15.45pm 04/09/2024 (20 minute delay) ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.